|
|
 |
|
Viewing report
|
|
|
|
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology
Bioseeker, Dec 2006, Pages: 350
In this triple analysis report the author has analyzed three major and intertwined areas of cancer R&D, Apoptopic agents, Antibodies and Vaccines in Oncology, which are all subjects to an extensive number of innovative drug candidates. This extensive 350+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the three mentioned key oncology areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
There are today over 190 apoptopic drugs in active development for the treatment of more than 40 different cancer indications. The top five pursued cancer indications are: breast cancer, leukemia, lung cancer, lymphoma and prostate cancer. A thorough target analysis of drugs in development reveals more than 130 candidate targets for triggering apoptosis in cancer cells.
Competitive forces are reviewed, showing market leaders, active players and changes in the competitive landscape. There are only one big pharma company represented among the top 10 players in apoptopic drug development in oncology. The acquisition of Idun Pharmaceutical in 2005 by Pfizer is principal example of a further step in big pharma strategy to augment their internal research and development efforts with high-potential, externally sourced product candidates and technologies.
Apoptopic Agents Highlights
- In-depth competitive landscape assessment of the apoptopic market in oncology
- Thorough review of utilized targets in apoptopic drug development
- Thorough review of approved drugs
- Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls
- Among the targeted therapies for cancer, immunotherapy is probably the most versatile treatment strategy for the eradication of tumors, metastatic spread or not. Main strategies of cancer immunotherapy aim at exploiting the therapeutic potential of tumor-specific antibodies and cellular immune effector mechanisms (vaccines).
Immunotherapy in Highlights
- In-depth competitive landscape assessment of the cancer immunotherapy market place; Including more than 200 immunotherapy drugs and pharmaceutical companies
- Thorough review of tumor antigen discovery, immunomodulating strategies and adjuvants
- Thorough review of antibody and vaccine delivery and technologies surrounding it - The next generation
- Progress analysis of six major cancer vaccine indications and late stage antibody development projects, including players, drugs, clinical progress and pitfalls
Customers who bought this item also bought
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Antibody Drug Targets and Focus on Breast & Prostate Cancer
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
Drug Delivery in Cancer - Technologies, Markets and Companies
Prostate and Breast Cancer- New Treatments & Developmental Progress
Triple Analysis: Decoding Big Pharma's R&D Strategy In Oncology and Special Focus on Breast and Prostate Cancer
Analytical Tool - Cancer Vaccines
Breast Cancer - Therapeutic And Competitive Insights
Prostate Cancer - A Therapeutic & Competitive Insight
Prostate Cancer Therapeutics - Global Strategic Business Report
Competitive Outlook on Non-Antibody Based Cancer Vaccines
|
|
|
|
